Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediGene Oncologic Imparts 30% Survival Advantage In Pancreatic Cancer Phase II

This article was originally published in The Pink Sheet Daily

Executive Summary

German firm also studies anti-angiogenesis drug in hormone-resistant breast cancer.

You may also be interested in...



MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility

Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.

MediGene’s ‘Airbag’ Equity Deal Provides EndoTAG-1 Partnering Flexibility

Option lets the firm sell up to 25M Euros in new stock to YA Global over three-year period.

Patient Death Halts Phase I Trial For MediGene RA Candidate

Talked up as a potential blockbuster, RhuDex produced positive Phase IIa findings a month earlier.

Topics

UsernamePublicRestriction

Register

PS067419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel